| Clinical Study "Common" Name (formal title) | Number of enrollees | Funding source (pharmaceutical company/National Institutes of Health [NIH]) | Year complete | Primary publication | Full study treatment protocol/patient disposition |
|---|---|---|---|---|---|
|
FIREFLEYE Effect of Intravitreal Aflibercept vs Laser Photocoagulation on Treatment Success of Retinopathy of Prematurity: The FIREFLEYE Randomized Clinical Trial |
192 |
Bayer AG: Regeneron Pharmaceuticals (NCT04004208) |
2021 | Stahl A, Sukgen EA, Wu WC, et al. Effect of Intravitreal Aflibercept vs Laser Photocoagulation on Treatment Success of Retinopathy of Prematurity: The FIREFLEYE Randomized Clinical Trial. JAMA. 2022;328:348-359. https://jamanetwork.com/journals/jama/article-abstract/2794566 |
|